共 134 条
[1]
Pegram MD(1998)Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J Clin Oncol 16 2659-2671
[2]
Lipton A(1979)Phase-II trial of tamoxifen in advanced breast cancer Cancer Chemother Pharmacol 3 45-48
[3]
Hayes DF(2007)The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329-2334
[4]
Weber BL(2007)Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database Cancer 110 876-884
[5]
Baselga JM(2006)Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 5652-5657
[6]
Tripathy D(2007)Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429-4434
[7]
Wiggans RG(2005)Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 917-921
[8]
Woolley PV(2011)Iniparib plus chemotherapy in metastatic triple-negative breast cancer N Engl J Med 364 205-214
[9]
Smythe T(2010)Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 235-244
[10]
Hoth D(2008)Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 1810-1816